Forty Seven (Forty Seven) EBIT : $-88.53 Mil (TTM As of Dec. 2019)

View and export this data going back to 2018. Start your Free Trial

What is Forty Seven EBIT?

Forty Seven's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2019 was $-24.56 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2019 was $-88.53 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Forty Seven's annualized ROC % for the quarter that ended in Dec. 2019 was -916.66%. Forty Seven's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2019 was -2,890.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Forty Seven's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2019 was -1.92%.

Forty Seven EBIT Historical Data

The historical data trend for Forty Seven's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forty Seven EBIT Chart

Forty Seven Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

EBIT

-19.62

-45.30

-72.11

-88.53

Forty Seven Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19
EBIT	Get a 7-Day Free Trial								-17.78	-23.71	-23.89	-16.37	-24.56

Competitive Comparison of Forty Seven's EBIT

For the Biotechnology subindustry, Forty Seven's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Forty Seven's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forty Seven's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Forty Seven's EV-to-EBIT falls into.

Forty Seven EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-88.53 Mil.

Forty Seven (NAS:FTSV) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Forty Seven's annualized ROC % for the quarter that ended in Dec. 2019 is calculated as:

	ROC % (Q: Dec. 2019 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2019 )	+	Invested Capital (Q: Dec. 2019 ))	/ count )
=	-98.252 * ( 1 - 0% )	/	( (10.277	+	11.16)	/ 2 )
=	-98.252	/	10.7185
=	-916.66 %

where

	Invested Capital		(Q: Sep. 2019 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	183.583	-	19.683	-	( 166.742	-	max(0, 23.702	-	177.325	+	166.742	))
=	10.277

	Invested Capital		(Q: Dec. 2019 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	343.593	-	17.704	-	( 329.094	-	max(0, 22.795	-	337.524	+	329.094	))
=	11.16

Note: The Operating Income data used here is four times the quarterly (Dec. 2019) data.

2. Joel Greenblatt's definition of Return on Capital:

Forty Seven's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2019 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2019 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2019		Q: Dec. 2019
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-98.252	/	( ( (3.597 + max(-11.685, 0))	+	(3.201 + max(-12.894, 0)) )	/	2 )
=	-98.252	/	( ( 3.597	+	3.201 )	/	2 )
=	-98.252	/	3.399
=	-2,890.61 %

where Working Capital is:

	Working Capital		(Q: Sep. 2019 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	10.583)	-	(19.683	+	2.585	+	0)
=	-11.685

	Working Capital		(Q: Dec. 2019 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	8.43)	-	(17.704	+	2.761	+	0.859)
=	-12.894

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2019) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Forty Seven's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2019 )
	=	-88.532	/	4599.400
	=	-1.92 %

Forty Seven EBIT Related Terms

Thank you for viewing the detailed overview of Forty Seven's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Forty Seven (Forty Seven) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forty Seven Inc (NAS:FTSV) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1490 Oâ€™Brien Drive, Suite A, Menlo Park, CA, USA, 94025

Website

https://www.fortyseveninc.com

Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.

Executives

Dennis Henner	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Kristine M Ball	director	C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Ann D Rhoads	officer: Chief Financial Officer	4000 NORTH FIRST STREET, SAN JOSE CA 95134
Ian T Clark	director	SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jeffrey W Bird	director	755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Lightspeed General Partner X, L.p.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Ultimate General Partner X, Ltd.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Jeremy Liew	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Venture Partners X, L.p.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Barry Eggers	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Peter Nieh	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Ravi Mhatre	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Stephen A Schwarzman	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c.	10 percent owner	C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Inc.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154